| Similar Articles |
|---|
 |
Chemistry World
June 26, 2012
Patrick Walter |
Roche cuts 1000 jobs with US R&D site closure The shuttering of its only East Coast R&D site is part of a streamlining drive which will see research activities from the Nutley site moved to Germany and Switzerland.   |
Chemistry World
October 15, 2013
Emily James |
Roche backs biologic boom The world's largest biotech company, Roche, has announced it will invest 800 million Swiss francs into manufacturing biological medicines over the next five years. |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
Chemistry World
April 5, 2013
Phillip Broadwith |
Roche to release Tamiflu trial data Swiss pharma company Roche has finally agreed to give independent researchers access to data on all 74 clinical trials it ran on the antiviral influenza drug Tamiflu (oseltamivir). |
Chemistry World
November 27, 2012
Andrew Turley |
Roche and the Tamiflu data The Swiss pharma company has agreed to talk to external groups about full access to data for antiviral Tamiflu (oseltamivir) tablets, according to a letter published by the British Medical Journal. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
The Motley Fool
August 22, 2007
Brian Orelli |
Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low. |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
The Motley Fool
July 16, 2007
Brian Orelli |
Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note. |
National Real Estate Investor
May 1, 2003
William Ikard |
Challenging the Tax Man The sizeable capital investments made in large corporate headquarters properties are not necessarily representative of market value. Therefore, a tax authority's reliance on original cost or replacement cost is not only unfair, it is just plain wrong. |
The Motley Fool
July 21, 2008
Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own. |
Fast Company
January 2002
George Anders |
Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents... |
Chemistry World
December 15, 2009
Sarah Houlton |
Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu. |
Pharmaceutical Executive
September 1, 2008
Walter Armstrong |
The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08. |
The Motley Fool
March 19, 2008
Brian Lawler |
Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera. |
Chemistry World
February 21, 2013
Andrew Turley |
$595m octreotide deal grabs Roche Swiss drugmaker Roche has struck a $595 million deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth |
Technology Research News
June 16, 2004
Ted Smalley Bowen |
Internet Ups Power Grid IQ Now that most building are wired into the Internet, the way is open for building managers to program buildings to adjust power use dynamically based on infrastructure, economic and environmental conditions. |
Pharmaceutical Executive
October 1, 2010 |
Roche Sets a New Social Media Standard Will Roche's precedent push the regulatory community to create standards that will level the playing field for all contenders? |
The Motley Fool
November 20, 2006
Karl Thiel |
Trimeris Begs for a Buyout The pharmaceutical's reorganization plan practically posts a "for sale" sign. So will Roche -- or someone else -- bite? Investors, take note. |
HBS Working Knowledge
March 21, 2005
Lauren Keller Johnson |
Tips for the CEO Candidate Think you're ready to step up to the top job? Get in line---there's plenty of competition. Here's advice for ascension from a top recruiter. |
The Motley Fool
April 5, 2004
Charly Travers |
A Biotech's Transition to Drugs A deal with Roche gives ArQule's drug program a leg up. ArQule has spent the last year transitioning from a services company into a drug developer. Last week's deal with Roche could signify that the transition is complete. |
The Motley Fool
February 25, 2009
Brian Orelli |
Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer. |
Bio-IT World
April 2007 |
News Briefs Molecular Medicine's "Best of Show"... Dissolving Assets... Combined Forces... |
The Motley Fool
January 31, 2008
Brian Lawler |
Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention. |
HBS Working Knowledge
January 12, 2004
Martha Lagace |
Does Your HQ Operation Fit With Corporate Strategy? Is a lean headquarters operation the key to success? How should headquarters design fit with corporate strategy? New research from professor David J. Collis has surprising answers. |
Chemistry World
January 28, 2015
Rebecca Trager |
Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
